教育背景

1. 2010/09-2014/07，复旦大学，病原生物学

2. 2004/09-2007/09，吉林医学院，医学检验

3. 1999/09-2004/07，吉林医学院，医学检验

工作经历

(1) 2019/10-至今，复旦大学，病原生物系

(2) 2016/09-2019/10，复旦大学，生物学，博士后

(3) 2014/08-2016/09，上海市疾病预防控制中心，病原生物检定所

(4) 2007/08-2011/08，浙江省台州医院，中心实验室

工作期间发表论文

1. Xia S#, Yan L#, Xu W#, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA*, Jiang S*, Yang B*, Lu L*., A Pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike, Sci Adv. 2019 Apr; 5(4): eaav4580.

2. Xu, W.#, Pu, J.#, Su, S.#, Hua, C., Su, X., Wang, Q., Jiang, S.*, Lu, L.* Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.AIDS. 2019 Aug 1;33(10):1545-1555.

3. Xu, W. #, Xia, S., Pu, J., Wang, Q., Li, P., Lu, L.*, Jiang, S*, (2018). The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. Front Microbiol. 2018 Nov 6;9:2643.

4. Xu, W., Daia, Y., Hua, C., Wang, Q., Zou, P., Deng, Q., Jiang, S.*, Lu, L.*.Genomic signature analysis of the recently emerged highly pathogenic A(H5N8) avian influenza virus: implying an evolutionary trend for bird-to-human transmission. Microbes Infect. 2017 Dec;19(12):597-604.

5. Xu, W. #, Wang, Q. #, Yu, F., Lu, L.*, Jiang, S.* (2014). Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs. J. Acquir. Immune Defic. Syndr. (JAIDS), 67(1):1-6. IF=4.425.

6. Xu, W. #, Lu, L #. Shen, B., Li, J., Xu, J., Jiang, S.* (2013). Serological investigation of subclinical influenza A (H7H9) infection among healthcare and non-healthcare workers in Zhejiang Province of China. Clin. Infect. Dis. 57(6):919-921. IF=9.374.

7. Xu, W. #, Sun, Z.,Liu, Q., Xu, J., Jiang, S.*, Lu, L.* (2013). PA-356R as a unique signature in avian influenza A(H7N9) virus possibly associated with the increased bird-to-human transmissibility and virulence: potential implication for animal surveillances. J. Infect. 67(5):490-494. IF=4.382

专利

1. 姜世勃，陆路，李雯，徐巍，一种抑制艾滋病病毒感染活性的多肽及其相关噬菌体，申请日期：2012.10.08，中国专利号：ZL201210379629.2，授权日期：2016.4.20

2. 姜世勃，陆路，徐巍，里卡多•罗塞纳，卢水秀，黄金，王瑞，一种长效HIV-1膜融合抑制剂，申请日：2013.06.28，中国专利号：ZL201310655778.1，授权日期：2016.08.17

3．陆路，姜世勃，徐巍，刘腾，王茜，花晨，王聪，付玉红，李佩玉。马来酸卡比沙明在制备抗流感病毒药物中的应用。申请日期：2018.08.29，中国专利申请号：201810996687.7

4．杨霞，姜世勃，陆路，徐巍，王茜，花晨。广谱抗微生物制剂、其制备方法及应用。申请日期：2018.06.28，中国专利申请号：201810691093.5